medigraphic.com

2014, Number 2

<< Back Next >>

Rev Cuba Endoc 2014; 25 (2)

Blood hypertension control in type 2 diabetic persons

Valdés RE, Verdecia SR, Rivera CM, Valdés BE

Language: Spanish
References: 35
Page: 76-86
PDF size: 135.28 Kb.


ABSTRACT

Objective: to evaluate the blood hypertension control and its relationship with some clinical and biochemical variables in type 2 diabetic persons living in Bayamo, Gramma province.
Methods: cross-sectional descriptive study of 382 type 2 diabetic and hypertensive patients, who were admitted to the Center of Care for Diabetic Patient in Bayamo, Gramma province in the period of September 2011 through May 2013. The patients were divided into 2 groups according to the blood hypertension control in terms of controlled and uncontrolled hypertensives.
Results: on discharge from hospital, 345 diabetic patients (90.3 %) had reached optimal control of their blood pressure. To attain this goal, it was necessary to use two or more drugs in 68.4 % of cases. The diabetics that did not succeed in this task were older and had longer time of progression of diabetes than those who did (p= 0.0126 y p= 0.0090, respectively). There was remarkable association of lack of glycemic control and uncontrolled blood pressure (OR= 6.82, IC= 3.3-13.9, p= 0.0000).
Conclusions: it was necessary to use two or more drugs to reach optimal control of blood pressure in most of the type 2 diabetic patients and to consider different factors such as age, time of diabetes progression and glycemic control.


REFERENCES

  1. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035-87.

  2. Valdés Ramos E, Bencosme Rodríguez N. Frecuencia de la hipertensión arterial y su relación con algunas variables clínicas en pacientes con diabetes mellitus tipo 2. Rev Cubana Endocrinol. 2009;20(3):77-88.

  3. Partridge EE, Mayer-Davis EJ, Sacco RL, Balch AJ. Creating a 21st century global health agenda: the General Assembly of the United Nations High Level Meeting on Non-Communicable Diseases. Circulation. 2011;123:3012-4.

  4. Cooper-Dehoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-8.

  5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93.

  6. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et-al. ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219.

  7. Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NR, et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 therapy. Can J Cardiol. 2010;26:249-58.

  8. Grossman E, Messerli FH, Goldbourt H. High blood pressure and diabetes mellitus. Are all antihypertensive drugs created equal? Arch Intern Med. 2000;160:2447-52.

  9. Cuba. Ministerio de Salud Pública. DNE. Anuario Estadístico de Salud, 2009. La Habana; 2011.

  10. Seventh Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JMCV). Hypertension. 2003;42:1206-52.

  11. World Health Organization (WHO). Definition and classification of diabetes mellitus and complications. Report of WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization, Department of Noncommunicable Desease Surveillance; 1999.

  12. World Health Organization (WHO). Expert Committee Phycal Status. The use and interpretation of anthropometry. Geneva: Technical Report; 1995. Series No. 854.

  13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.

  14. L´Esperance FA. Diabetic retinopathy. Ophthalmic Laser Fotocoagulation, photoradiation and surgery. In: L´Esperance FA (Jr). Diabetic Retinopathy. St Louis-Toronto-Londres: Ed. Mosby; 1983. p. 275-85.

  15. Escobar F. Pie diabético y factores de riesgo. Av Diabetol. 1995;5:71-6.

  16. Schettler G, Nüssel E. Cholesterol CHOP-PAP. Arb Med Loz Med Präv Med. 1975;10:25.

  17. Schettler G, Nüssel E. Triglyceride liquicolor GPO-PAP. Arb Med Loz Med Präv Med. 1975;10:25.

  18. Trinder P. Determination of glucose in blood using glucose oxidase with on alternative oxigen acceptor. Clin Biochem. 1996;24-7.

  19. Colectivo de Autores. Primer consenso cubano de dislipoproteinemias: Guía para la prevención, detección, diagnóstico y tratamiento. Rev Cubana Endocrinol. 2006;17(4):1-31.

  20. Cordero A, Facila L, Galve E, Mazon P. Novedades en hipertensión arterial y diabetes mellitus. Rev Esp Cardiol. 2010;63 Supl 1:101-15.

  21. Basta E. Choices and goals in teatment of diabetic hypertensive patient. Current Hypert Reports. 2001;35:387-91.

  22. Licea Puig ME, Singh Linares O, Smith Limonta A, Martínez García R. Frecuencia, características clínicas y resultados terapéuticos de la hipertensión arterial en diabéticos tipo 2 de un área de salud. Rev Cubana Endocrinol [serie en Internet]. 2002 Ago [citado 11 de noviembre de 2013];13(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561- 29532002000200007&lng=es&nrm=iso&tlng=es

  23. Hipertensión: Manejo clínico de hipertensión primaria en adultos [homepage en Internet]. Traducción de NICE clinical guideline 127; agosto 2011 [citado 30 de julio de 2013]. Disponible en: http://www.nice.org.uk/guidance/CG127

  24. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33 Suppl 1:S11-61.

  25. Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907-17.

  26. Ruggenenti P, Fassi A, Ilieva AP, for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing Microalbuminuria in Type 2 Diabetes. N Engl J Med. 2004;351:1941-51.

  27. Méndez JD, Xie J, Aguilar M, Méndez V. Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol Cell Biochem [serie en Internet]. 2010 [citado 15 de junio de 2013];10(1-2). Disponible en: http://link.springer.com/article/10.1007%2Fs11010-010-0434-5

  28. Ceriello A. La "memoria metabólica" inducida por la hiperglucemia: el nuevo reto en la prevención de la enfermedad cardiovascular en la diabetes. Rev Esp Cardiol. 2008;8(Supl C):12-8.

  29. Chuang SY, Chou P, Hsu PF, Cheng HM, Tsai ST, Lin IF, et al. Presence and progression of abdominal obesity are predictors of future high blood pressure and hypertension. Am J Hypertens. 2006;19:788-95.

  30. Kim SH, Reaven GM. Insulin resistance and hyperinsulinemia: you can't have one without the other. Diabetes Care. 2008;31(7):1433-8.

  31. Poirier P. Cardiologists and abdominal obesity: lost in translation? Heart. 2009;95:1033-5.

  32. Cinza Sanjurjo S, Días Hoyos R. Grado de control de la presión arterial en pacientes crónicos de Atención Primaria. Publicado en Semergen. 2010;36(10):554-61.

  33. Seshasai SR, Kaptoge S, Thompson A, Di AE, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-41.

  34. Vinagre I, Mata-Cases M, Hermosilla E, Morros R, Fina F, Rosell M, et al. Control of Glycemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes in Primary Care in Catalonia (Spain). Diabetes Care. 2012;35:774-9.

  35. Valdés Ramos E, Bencosme Rodríguez N. Las complicaciones macrovasculares y su relación con algunas variables clínicas y bioquímicas en diabéticos tipo 2. Rev Cubana Endocrinol. 2010 Dic;21(3):256-68.




2020     |     www.medigraphic.com